Carmen Leblanc, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1477744704
Payments from drug & device makers
Across 375 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Insulet Corporation$965
- Medtronic$587
- Novo Nordisk$583
- Novartis$477
- Amgen$451
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$2503%
- Food & beverage$6,96796%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 69 | $1,096 |
| Insulet Corporation | 45 | $965 |
| Medtronic(2 entities) | 27 | $587 |
| Novo Nordisk | 36 | $583 |
| Novartis | 24 | $477 |
| Amgen(2 entities) | 26 | $451 |
| Mannkind Corporation | 10 | $272 |
| Tandem Diabetes Care, Inc. | 1 | $250 |
| Boehringer Ingelheim | 15 | $235 |
| Lilly USA, LLC | 12 | $231 |
| Sanofi-aventis U.S. LLC | 11 | $177 |
| Corcept Therapeutics | 10 | $173 |
| Companion Medical, Inc. | 2 | $171 |
| Valeritas, Inc. | 8 | $158 |
| Bigfoot Biomedical Inc | 1 | $152 |
| BD | 8 | $147 |
| Dexcom, Inc. | 7 | $116 |
| AbbVie | 6 | $114 |
| Amarin Pharma, Inc. | 6 | $108 |
| Kvk-tech, Inc. | 7 | $103 |
| IBSA Pharma Inc. | 5 | $87 |
| Zealand Pharma US, Inc. | 4 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $76 |
| AstraZeneca(2 entities) | 5 | $72 |
| Cequr Corporation | 5 | $71 |
| Amneal Pharmaceuticals LLC | 3 | $44 |
| Lifescan, Inc. | 3 | $42 |
| Merck | 3 | $35 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Nalpropion Pharmaceuticals LLC | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Vivus LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,240 in reported general payments places this provider in the 65th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $111,069 |
| TrulicityDulaglutide | 75 | $106,735 |
| MounjaroTirzepatide | 45 | $85,810 |
| JardianceEmpagliflozin | 57 | $53,936 |
| FarxigaDapagliflozin Propanediol | 42 | $48,265 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $47,852 |
| TradjentaLinagliptin | 50 | $41,558 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $30,539 |
| Bydureon BciseExenatide Microspheres | 19 | $25,678 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $23,676 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $22,730 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $18,223 |
| SynthroidLevothyroxine Sodium | 218 | $17,725 |
| Novolog FlexpenInsulin Aspart | 61 | $17,360 |
| Humulin R U-500Insulin Regular, Human | 11 | $15,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $231 | $199,965168 claims |
| Novo NordiskOzempic, Novolog | $583 | $120,409110 claims |
| Boehringer IngelheimJardiance, Tradjenta | $235 | $95,494107 claims |
| AstraZenecaFarxiga | $72 | $48,26542 claims |
| MerckJanumet, Januvia | $35 | $37,42344 claims |
| AbbVieSynthroid | $114 | $17,725218 claims |
| Johnson & JohnsonInvokana | $15 | $15,10314 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $44 | $1,609182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
- Lawrence PhillipsAtlanta$919K
- Georgia DavisAtlanta$592K
- Jonathan OwnbyAtlanta$565K
- Thaer IdreesAtlanta$505K
- Francisco PasquelAtlanta$376K
- Mary RheeAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.